Konrad Klinghammer

List of Publications by Year
in descending order

27 papers	**544** citations	687220 **13** h-index	642610 **23** g-index
28 all docs	**28** docs citations	**28** times ranked	**1148** citing authors

#	Article	IF	Citations
1	Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximabâ€"Docetaxel Treatment. Clinical Cancer Research, 2011, 17, 5197-5204.	3.2	85
2	Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment. Clinical Cancer Research, 2010, 16, 304-310.	3.2	60
3	A comprehensively characterized large panel of head and neck cancer patientâ€derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option. International Journal of Cancer, 2015, 136, 2940-2948.	2.3	53
4	Reactive oxygen species in cancer stem cells of head and neck squamous cancer. Seminars in Cancer Biology, 2018, 53, 248-257.	4.3	44
5	Choosing wisely â€" Preclinical test models in the era of precision medicine. Cancer Treatment Reviews, 2017, 55, 36-45.	3.4	37
6	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. Oncotarget, 2016, 7, 75379-75393.	0.8	27
7	Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. Cancers of the Head & Neck, 2020, 5, 9.	6.2	25
8	Support of a molecular tumour board by an evidence-based decision management system for precision oncology. European Journal of Cancer, 2020, 127, 41-51.	1.3	25
9	Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer. International Journal of Cancer, 2017, 141, 1215-1221.	2.3	24
10	Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. Cells, 2021, 10, 517.	1.8	20
11	PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximabâ€docetaxel. Head and Neck, 2015, 37, 471-478.	0.9	19
12	Targeted Therapy of Head and Neck Cancer. Oncology Research and Treatment, 2016, 39, 780-786.	0.8	17
13	Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). European Journal of Cancer, 2019, 122, 53-60.	1.3	16
14	Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. Oncotarget, 2020, 11, 3688-3697.	0.8	13
15	Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma. British Journal of Cancer, 2020, 122, 835-846.	2.9	11
16	Distinct immune evasion in APOBECâ€enriched, HPVâ€negative HNSCC. International Journal of Cancer, 2020, 147, 2293-2302.	2.3	10
17	Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets. International Journal of Cancer, 2021, 149, 1166-1180.	2.3	10
18	A multilayered epithelial mucosa model of head neck squamous cell carcinoma for analysis of tumor-microenvironment interactions and drug development. Biomaterials, 2020, 258, 120277.	5.7	9

#	Article	IF	Citations
19	Developmental delay in hypoxia-induced HO-1 expression predisposes to gut injury. Journal of Perinatal Medicine, 2012, 40, 191-7.	0.6	6
20	pN status predicts outcomes in surgically treated pT1â€"pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study. European Archives of Oto-Rhino-Laryngology, 2018, 275, 2787-2795.	0.8	6
21	Animal models for personalized treatment options. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 698-700.	0.3	6
22	Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers. Cancers, 2022, 14, 2810.	1.7	6
23	A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck â€" the RESGEX study. ESMO Open, 2021, 6, 100242.	2.0	5
24	Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study. European Journal of Cancer, 2022, 169, 146-155.	1.3	4
25	Predictors for Adherence to Treatment Strategies in Elderly HNSCC Patients. Cancers, 2022, 14, 423.	1.7	3
26	A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers. International Journal of Cancer, 2018, 142, 156-164.	2.3	2
27	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group. Frontiers in Oncology, 2022, 12, 730785.	1.3	1